|
| 37794811 | BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study. | Haematologica | 2024 |
| 36251440 | Circulating cell-free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre-analytical biases. | Hematol Oncol | 2023 |
| 37760592 | Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study. | Cancers (Basel) | 2023 |
| 37914482 | 10-day decitabine versus 3â¿¿+â¿¿7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. | Lancet Haematol | 2023 |
| 37705525 | Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience. | Mediterr J Hematol Infect Dis | 2023 |
| 37700538 | Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study. | Br J Haematol | 2023 |
| 37838758 | Measurable residual disease in chronic lymphocytic leukemia. Where do we stand? | Leukemia | 2023 |
| 37580908 | XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling. | Br J Haematol | 2023 |
| 35770529 | Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling. | Haematologica | 2023 |
| 35849302 | Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report. | Hematol Oncol | 2023 |
| 37354090 | Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: AÂ study from the Registro Italiano LMC and Campus CML. | Cancer | 2023 |
| 37392141 | Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. AÂ campus chronic lymphocytic leukemia study. | Hematol Oncol | 2023 |
| 37452789 | Digital droplet PCR for T315I BCR::ABL1 KD mutation assessment in adult Ph-positive acute lymphoblastic leukemia with a minimal residual disease increase. | Leuk Lymphoma | 2023 |
| 37016899 | A five-gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia. | Hematol Oncol | 2023 |
| 37314420 | Minimal residual disease in Philadelphia-positive acute lymphoblastic leukemia: Maximizing the clinical yield of testing. | Am J Hematol | 2023 |
| 37046814 | Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity. | Cancers (Basel) | 2023 |
| 37382471 | Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. | Am J Hematol | 2023 |
| 37276451 | Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. | Blood Adv | 2023 |
| 37173879 | Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2023 |
| 37033642 | Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study. | Front Pharmacol | 2023 |
| 37357817 | Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients. | Br J Haematol | 2023 |
| 36959485 | Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study. | Ann Hematol | 2023 |
| 36779594 | Sialylation regulates migration in chronic lymphocytic leukemia. | Haematologica | 2023 |
| 36807650 | Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study. | Leukemia | 2023 |
| 36540957 | The evolution of frontline therapy for adult Philadelphia-positive acute lymphoblastic leukemia: Giant strides and ongoing challenges. | Am J Hematol | 2023 |
| 36869099 | Daniel Catovsky (1937-2022). | Leukemia | 2023 |
| 36533589 | ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings. | Leuk Lymphoma | 2023 |
| 36733349 | Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia. | Front Oncol | 2023 |
| 36672325 | Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2023 |
| 36599847 | Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. | Blood Cancer J | 2023 |
| 36632738 | High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. | Haematologica | 2023 |
| 36793194 | Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature. | Br J Haematol | 2023 |
| 36335916 | Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study. | Br J Haematol | 2023 |
| 35981563 | Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities. | Blood | 2023 |
| 36349541 | Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. | Am J Hematol | 2023 |
| 36190298 | Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia. | Hematol Oncol | 2023 |
| 34284384 | Myeloid Sarcoma: Diagnostic and Treatment Tools from a Monocentric Retrospective Experience. | Acta Haematol | 2022 |
| 35710027 | Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia. | J Mol Diagn | 2022 |
| 35615334 | Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report. | Mediterr J Hematol Infect Dis | 2022 |
| 35443561 | COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report. | Haematologica | 2022 |
| 35543676 | Immuno-hematological monitoring after allogeneic stem cell transplantation: a single-center, prospective study of 104 patients. | Blood Transfus | 2022 |
| 35731654 | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. | N Engl J Med | 2022 |
| 35499213 | Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall. | Br J Haematol | 2022 |
| 35385922 | Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study. | Haematologica | 2022 |
| 36479077 | Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study. | Front Oncol | 2022 |
| 36233461 | Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation. | J Clin Med | 2022 |
| 36028857 | Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL. | J Hematol Oncol | 2022 |
| 36155352 | Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group. | Leuk Res | 2022 |
| 35913400 | Early CD49d downmodulation in chronic lymphocytic leukemia patients treated front-line with ibrutinib plus rituximab predicts long-term response. | Leuk Lymphoma | 2022 |
| 35913396 | Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation. | Leuk Lymphoma | 2022 |